Yesterday, POSC share price closed again at the $0.075 resistance after rising by 7.14% during the day. The last trading alerts were sent in the middle of the month and this time they did not come from the previous paid promoter. The next resistance is at $0.09, but the trading volumes are growing again and breaking it will maybe depend on what kind of perspectives the next coming PR will bring.
POSC remains by now silent about the details from its milestone strategic partnership with Covidien (NYSE:COV), probably keeping the story secret until the stock has gained enough market value for the real bounce off. The latest few announcements were not less encouraging for traders, however.
Although it is doubtful if POSC will be able to fulfill the announced last week further growth plans, business developments and strategic alliances with around $3.4 million in cash, it is a fact that their stock is reviving. That revitalization coincided, as by surprise, again with a press release from the company.
It came out three weeks ago and concerned POSC’ Attrius PET system, which is currently its only product that sells, making up a substantial part of the revenues. The sales from Attrius PET jumped six times year-over-year during the first half of this year.
They were in the range of $1 million for the last six-months period, which makes the mentioned in the PR value of $10 to $12 million, to be reached by the end of this year, sound like a too optimistic point of view.
